



AL 13/T.P.  
Dillen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1805

Examiner: Mr. David Guzo

10/22/97

In re PATENT APPLICATION of:

Applicants : Richard Harris WILSON et al.)

Application No.: 08/476,567 )

Filed : June 7, 1995 )

For : RECOMBINANT DNA SEQUENCES, )  
VECTORS CONTAINING THEM )  
AND METHOD FOR THE USE )  
THEREOF )

**TERMINAL  
DISCLAIMER**

Attorney Docket: CARPR 0022C3 )

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Celltech Limited, located at 216 Bath Road, Slough, Berkshire SL2 4EN, England, a British Company, and The University Court of the University of Glasgow, located at 502 University Court of the University of Glasgow, The University Avenue, Glasgow, G12 8QQ, Glasgow, Scotland, a corporation of Great Britain, assignees of the entire right, title and interest in the above-identified application by virtue of an Assignment recorded at the United States Patent and Trademark at Reel 4790, Frame 0784, on October 22, 1987, hereby disclaims except as provided below the terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the earlier of the full statutory term defined in 35 U.S.C. §154 and §156 of

FEE Enclosed: \$110.00  
Please charge any further  
fee to Dep.Acct. 19-3700.

any patent granted on U.S. application No. 08/302,241 and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patent granted on U.S. application No. 08/302,241, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors of assigns.

In making the above disclaimer, petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the term defined in 35 U.S.C. §154 in the event that U.S. application No. 08/302,241 expires for failure to pay a maintenance fee, is held unenforceable or is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimer under 37 C.F.R. §1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise not deemed to provide the rights conveyed by 35 U.S.C. §154 prior to the expiration of its full statutory term, except for the separation of legal title stated above.

The undersigned is the assignee of the above patent application by virtue of an assignment recorded in the United States Patent and Trademark Office on October 22, 1987 at Reel 4790, Frame 0784. The assignment has been reviewed and it is certified that, to the best of the knowledge and belief of the

assignee, acting through the undersigned, title is in the assignee.

Done this 24th day of September, 1997 by the undersigned officer of CELLTECH THERAPEUTICS LIMITED (formerly known as CELLTECH LIMITED) and THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW both duly authorized to act for the assignee under the laws of the United Kingdom.

By 

Name: DAVID PHILIP BLOXHAM

Title: CHIEF OPERATING OFFICER

By 

Name: R.W.L. BLACKMORE

Title: IPR MANAGER.